[Clinical study of viloxazine (author's transl)].
An open study of viloxazine has been achieved in a psychiatric unit. The drug has been prescribed to 36 patients, all comers, half of them aged 60. Out of them 28 are affected by a psychotic depression, six by a neurotic depression. In terms of the importance of the depressive signs, medium posologies (300 mg a day) or strong ones (600 mg a day) are used. The total result is excellent or good in 65% of the cases: it becomes evident in more than one case out of two during the first week. To get it the treatment must absolutely be extended and process to higher posologies may be necessary. Involutional melancholia and the depressive phase of chronic psychosis constitute the best terms of viloxazine. Hypnotics have to be associated but systematic prescription of anxiety relieving is to be avoided. Tolerance is satisfactory in three cases out of four and the drug is free from the clinical counter-indications belonging to anti-depressants. This allows us to prescribe it to old age in high posologies without any harm.
D003863:Depression / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D014745:Viloxazine / Q000627:therapeutic use*
D009025:Morpholines; D014745:Viloxazine
L'étude clinique de la viloxazine.